Treatment of Brain Metastasis of Small Cell Lung Cancer with PD-1 Inhibitor: A Case Report

Authors

  • Sen Yang Department of Oncology, Hebei General Hospital, Shijiazhuang, Hebei, China; Graduate School of North China University of Science and Technology, Tangshan, Hebei, China
  • Xiaohui Han Department of Oncology, Hebei General Hospital, Shijiazhuang, Hebei, China; Hebei Medical University, Shijiazhuang, Hebei, China
  • Shihua Liu Department of Oncology, Hebei General Hospital, Shijiazhuang, Hebei, China; Graduate School of Hebei North University, Zhangjiakou, Hebei, China
  • Jianqiang Lan Department of Oncology, Hebei General Hospital, Shijiazhuang, Hebei, China; Graduate School of North China University of Science and Technology, Tangshan, Hebei, China
  • Aixia Sui Department of Oncology, Hebei General Hospital, Shijiazhuang, Hebei, China

Keywords:

small cell lung cancer, PD-1 inhibitor, Toripalimab

Abstract

PD-L1 (Programmed Cell Death Protein L1) inhibitor has been used in the first-line treatment of extensive small cell lung cancer, but its prognosis is still poor and its survival time is short, especially in patients with brain metastasis. The effect of PD-1 inhibitor is not satisfactory as well. PD-1 (Programmed Cell Death Protein 1) inhibitors are less effective and used in the third-line treatment, and patients only experience short PSF benefit. Herein, we report a unique case of a patient with brain and adrenal metastases of small cell lung cancer for whom brain metastases partially disappeared, efficacy evaluation at 25 months follow - up PR, quality of life was good, and no significant adverse effects were observed after receiving comprehensive treatment with PD-1 inhibitor Toripalimab.

Downloads

Published

2023-12-05

Issue

Vol. 2 No. 4 (2023): December

Section

Articles